Advertisement

Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell

      Highlights

      • Significant difference exists in outcomes of haplo-identical transplant following bone marrow compared to G-CSF mobilised peripheral stem cells.
      • The conditioning regimen needs to be tailored to the source of stem cells.
      • Some regimens are associated with significantly increased risk of viral infections.
      • Randomised studies are lacking.

      Abstract

      Haplo-identical transplant is being increasingly used in patients who do not have a readily available matched related or unrelated donor. Post-transplant cyclophosphamide’s use due to its simplicity and documented efficacy has made this approach readily employable across diverse transplant centres across the globe. The outcomes of regimens used for conditioning in recipients of bone marrow are at times in variance to that from more commonly employed G-CSF mobilised peripheral stem cell (PBSC). This review highlights various conditioning regimens used in PBSC recipients, with emphasis on toxicities, practicalities and transplant related outcomes of relapse, non-relapse mortality and graft versus host disease.

      Keywords

      To read this article in full you will need to make a payment
      ESMO Member Login
      Login with your ESMO username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Niederwieser D.
        • Baldomero H.
        • Szer J.
        • Gratwohl M.
        • Aljurf M.
        • Atsuta Y.
        • Bouzas L.F.
        • Confer D.
        • Greinix H.
        • Horowitz M.
        • Iida M.
        • Lipton J.
        • Mohty M.
        • Novitzky N.
        • Nunez J.
        • Passweg J.
        • Pasquini M.C.
        • Kodera Y.
        • Apperley J.
        • Seber A.
        • Gratwohl A.
        Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey.
        Bone Marrow Transplant. 2016; 51: 778-785https://doi.org/10.1038/bmt.2016.18
        • Scott B.
        • Pasquini M.
        • Logan B.
        • et al.
        Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.
        J Clin Oncol. 2017; 35: 1154-1161
        • Bradstock K.
        • Bilmon I.
        • Kwan J.
        • et al.
        Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigene matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease.
        Biol Blood Marrow Transplant. 2015; 21: 934-953
        • Eastburg L.
        • Russler-Germain D.
        • Abboud R.
        • et al.
        Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical SCT with post-transplant cyclophosphamide.
        Blood. 2019; 134: 4496
        • Ciurea S.
        The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.
        Bone Marrow Transplant. 2020; 55: 12-24
        • Ciurea S.
        • Cao K.
        • Fernandez-Vina M.
        • et al.
        The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation.
        Bone Marrow Transplant. 2018; 53: 521-534
        • Bacigalupo A.
        • Ballen K.
        • Rizzo D.
        • et al.
        Defining the intensity of conditioning regimens: working definitions.
        Biol Blood Marrow Transplant. 2009; 15: 1628-1633
        • Giralt S.
        • Ballen K.
        • Rizzo D.
        • et al.
        Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant.
        Research. Biol Blood Marrow Transplant. 2009; 15: 367-369
        • Solomon S.
        • Solh M.
        • Zhang X.
        • et al.
        Fludarabine and total-body irradiation conditioning before ablative haploidentical transplantation: long-term safety and efficacy.
        Biol Blood Marrow Transplant. 2019; 25: 2211-2216
        • Raiola A.
        • Dominietto A.
        • Ghiso A.
        • et al.
        Unmanipulated haploidentical bone marrowtransplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
        Biol Blood Marrow Transplant. 2013; 19: 117-122
        • Fasslrinner F.
        • Schetelig J.
        • Burchert A.
        • et al.
        Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
        Lancet Haematol. 2018; 5: 161-169
        • Solomon S.
        • Sizemore C.
        • Sanacore M.
        • et al.
        Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
        Biol Blood Marrow Transplant. 2012; 18: 1859-1866
        • Gilis L.
        • Morisset S.
        • Billaud G.
        • et al.
        High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation.
        Bone Marrow Transplant. 2014; 49: 664-670
        • Grosso D.
        • Gaballa S.
        • Alpdogan O.
        • et al.
        A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease.
        Biol Blood Marrow Transplant. 2015; 21: 646-652
        • Cieri N.
        • Greco R.
        • Crucitti L.
        • et al.
        Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells.
        Biol Blood Marrow Transplant. 2015; 21: 1506-1514
        • Danylesko I.
        • Shimoni A.
        • Nagler A.
        • et al.
        Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
        Bone Marrow Transplant. 2012; 47: 5-14
        • Cutler C.
        • Li S.
        • Ho V.
        • et al.
        Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
        Blood. 2007; 109: 3108-3114
      1. CIBMTR Annual report 2018.

        • Brammer J.
        • Khouri I.
        • Gaballa S.
        • et al.
        Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning.
        Biol Blood Marrow Transplant. 2016; 22: 493-498
        • Ciurea S.
        • Shah M.
        • Saliba R.
        • et al.
        Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome.
        Biol Blood Marrow Transplant. 2018; 24: 1232-1236
        • Pagliardini T.
        • Castagna L.
        • Harbi S.
        • et al.
        Thiotepa, fludarabine, and busulfan conditioning regimen before T cell_replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: A bicentric experience of 100 patients.
        Biol Blood Marrow Transplant. 2019; 25: 1803-1809
        • Dulery R.
        • Bastos J.
        • Paviglianiti A.
        • et al.
        Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation.
        Biol Blood Marrow Transplant. 2019; 25: 1407-1415
        • Sugita J.
        • Kawashima N.
        • Fujisaki T.
        • et al.
        HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning.
        Biol Blood Marrow Transplant. 2015; 21: 1646-1652
        • Luznik L.
        • O’Donnell P.
        • Symons H.
        • et al.
        HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
        Biol Blood Marrow Transplant. 2008; 14: 641-650
        • Raj K.
        • Pagliuca A.
        • Bradstock K.
        • et al.
        Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.
        Biol Blood Marrow Transplant. 2014; 20: 881-903